Expression and Prognostic Significance of APE1/Ref-1 and NPM1 Proteins in High-Grade Ovarian Serous Cancer

American Journal of Clinical Pathology

Volumn 141, Issue 3, 2014, Pages 404-414

  Londero, Ambrogio P ^a   Orsaria, Maria ^a   Tell, Gianluca ^a   Marzinotto, Stefania ^a   Capodicasa, Valentina ^a   Poletto, Mattia ^a   Vascotto, Carlo ^a   Sacco, Cosimo ^b   Mariuzzi, Laura ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

APE1 Ref 1; NPM1; Ovarian cancer; Prognostic factors; Survival

Indexed keywords

APURINIC ENDONUCLEASE; CARBOPLATIN; ENDONUCLEASE; NUCLEOPHOSMIN; PACLITAXEL; REDOX EFFECTOR FACTOR 1; UNCLASSIFIED DRUG; APEX1 PROTEIN, HUMAN; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; NUCLEAR PROTEIN;

ADJUVANT THERAPY; ADULT; AGE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR INVASION; AGED; APE1/REF-1; CANCER GRADING; CYSTADENOCARCINOMA; DNA REPAIR; METABOLISM; NPM1; OVARY TUMOR; PATHOLOGY; PROGNOSIS; PROGNOSTIC FACTORS; SURVIVAL; VERY ELDERLY;

APE1/REF-1; NPM1; OVARIAN CANCER; PROGNOSTIC FACTORS; SURVIVAL;

AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; DNA REPAIR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84897931222     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPIDKDLSGE26CX     Document Type: Article

References (36)

1. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415-428.
2. Ratner ES, Sartorelli AC, Lin ZP. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol. 2012;24:564-571.
3. Alvero AB, Chen R, Fu HH, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009;8:158-166.
4. Wilson DM III, Simeonov A. Small molecule inhibitors of DNA repair nuclease activities of APE1. Cell Mol Life Sci. 2010;67:3621-3631.
5. Kothandapani A, Dangeti VSMN, Brown AR, et al. Novel role of base excision repair in mediating cisplatin cytotoxicity. J Biol Chem. 2011;286:14564-14574.
6. Sengupta S, Mantha AK, Mitra S, et al. Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. Oncogene. 2011;30:482-493.
7. Arora S, Kothandapani A, Tillison K, et al. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair (Amst). 2010;9:745-753.
8. Wu HH, Cheng YW, Chang JT, et al. Subcellular localization of apurinic endonuclease 1 promotes lung tumor aggressiveness via NF-kappaB activation. Oncogene. 2010;29:4330-4340.
9. Tell G, Fantini D, Quadrifoglio F. Understanding different functions of mammalian AP endonuclease (APE1) as a promising tool for cancer treatment. Cell Mol Life Sci. 2010;67:3589-3608.
10. Kelley MR, Georgiadis MM, Fishel ML. APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Curr Mol Pharmacol. 2012;5:36-53.
11. Tell G, Damante G, Caldwell D, et al. The intracellular localization of APE1/Ref-1: more than a passive phenomenon? Antioxid Redox Signal. 2005;7:367-384.
12. Xanthoudakis S, Miao GG, Curran T. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. Proc Natl Acad Sci U S A. 1994;91:23-27.
13. Frehlick LJ, Eirín-López JM, Ausió J. New insights into the nucleophosmin/nucleoplasmin family of nuclear chaperones. Bioessays. 2007;29:49-59.
14. Szebeni A, Hingorani K, Negi S, et al. Role of protein kinase CK2 phosphorylation in the molecular chaperone activity of nucleolar protein b23. J Biol Chem. 2003;278:9107-9115.
15. Savkur RS, Olson MO. Preferential cleavage in pre-ribosomal RNA byprotein B23 endoribonuclease. Nucleic Acids Res. 1998;26:4508-4515.
16. Wang HF, Takenaka K, Nakanishi A, et al. BRCA2 and nucleophosmin coregulate centrosome amplification and form a complex with the Rho effector kinase ROCK2. Cancer Res. 2011;71:68-77.
17. Tell G, Wilson DM III, Lee CH. Intrusion of a DNA repair protein in the RNome world: is this the beginning of a new era? Mol Cell Biol. 2010;30:366-371.
18. Vascotto C, Fantini D, Romanello M, et al. APE1/Ref-1 interacts with NPM1 within nucleoli and plays a role in the rRNA quality control process. Mol Cell Biol. 2009;29:1834-1854.
19. Vascotto C, Lirussi L, Poletto M, et al. Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology. Oncogene. 2013. doi:10.1038/onc.2013.251.
20. Di Maso V, Avellini C, Crocè LS, et al. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med. 2007;13:89-96.
21. Kakolyris S, Kaklamanis L, Giatromanolaki A, et al. Expression and subcellular localization of human AP endonuclease 1 (HAP1/Ref-1) protein: a basis for its role in human disease. Histopathology. 1998;33:561-569.
22. Yun JP, Miao J, Chen GG, et al. Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters. Br J Cancer. 2007;96:477-484.
23. Bobola MS, Blank A, Berger MS, et al. Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin Cancer Res. 2001;7:3510-3518.
24. Robertson KA, Bullock HA, Xu Y, et al. Altered expression of Ape1/Ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res. 2001;61:2220-2225.
25. Rossi O, Carrozzino F, Cappelli E, et al. Analysis of repair of abasic sites in early onset breast cancer patients. Int J Cancer. 2000;85:21-26.
26. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28:496-504.
27. Vang R, Shih IM, Kurman RJ. Ovarian low-grade and highgrade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16:267-282.
28. Heintz APM, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary: FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(suppl 1):S161-S192.
29. Gospodarowicz M, Wittekind C, Sobin L, et al. TNM Classification of Malignant Tumours. 7th ed. New York, NY: Wiley-Blackwell; 2009.
30. Al-Attar A, Gossage L, Fareed KR, et al. Human apurinic/ apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. Br J Cancer. 2010;102:704-709.
31. Fantini D, Vascotto C, Marasco D, et al. Critical lysine residues within the overlooked N-terminal domain of human APE1 regulate its biological functions. Nucleic Acids Res. 2010;38:8239-8256.
32. Vascotto C, Cesaratto L, Zeef LAH, et al. Genomewide analysis and proteomic studies reveal APE1/Ref-1 multifunctional role in mammalian cells. Proteomics. 2009;9:1058-1074.
33. Vascotto C, Bisetto E, Li M, et al. Knock-in reconstitution studies reveal an unexpected role of Cys-65 in regulating APE1/Ref-1 subcellular trafficking and function. Mol Biol Cell. 2011;22:3887-3901.
34. Cicchillitti L, Di Michele M, Urbani A, et al. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. J Proteome Res. 2009;8:1902-1912.
35. Cicchillitti L, Della Corte A, Di Michele M, et al. Characterisation of a multimeric protein complex associated with ERp57 within the nucleus in paclitaxel-sensitive and -resistant epithelial ovarian cancer cells: the involvement of specific conformational states of beta-actin. Int J Oncol. 2010;37:445-454.
36. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6.